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Abstract
Ovarian epithelial tumors are an hallmark of hereditary cancer syndromes which are related to the
germ-line inheritance of cancer predisposing mutations in BRCA1 and BRCA2 genes. Although
these genes have been associated with multiple different physiologic functions, they share an
important role in DNA repair mechanisms and therefore in the whole genomic integrity control.
These findings have risen a variety of issues in terms of treatment and prevention of breast and
ovarian tumors arising in this context. Enhanced sensitivity to platinum-based anticancer drugs has
been related to BRCA1/2 functional loss. Retrospective studies disclosed differential
chemosensitivity profiles of BRCA1/2-related as compared to "sporadic" ovarian cancer and led to
the identification of a "BRCA-ness" phenotype of ovarian cancer, which includes inherited BRCA1/
2 germ-line mutations, a serous high grade histology highly sensitive to platinum derivatives.
Molecularly-based tailored treatments of human tumors are an emerging issue in the "era" of
molecular targeted drugs and molecular profiling technologies. We will critically discuss if the
genetic background of ovarian cancer can indeed represent a determinant issue for decision making
in the treatment selection and how the provocative preclinical findings might be translated in the
therapeutic scenario. The presently available preclinical and clinical evidence clearly indicates that
genetic background has an emerging role in treatment individualization for ovarian cancer patients.
Background
BRCA1 and BRCA2 are onco-suppressor genes involved in
several crucial molecular events such as DNA repair, cell
cycle regulation, apoptosis and genome integrity control
[1]. More than 2,600 cancer predisposing mutations have
been identified in BRCA1 and BRCA2 genes, on chromo-
some 17 and 13 respectively [2]. The genetic transmission
follows a pattern of mendellian dominant inheritance
with an approximate frequency of 1/800 in the Cauca-
sians and 1/50 in the Ashkenazy jews. These mutations
have been related to hereditary breast and ovarian cancer
but also to prostate cancer, colon cancer, pancreatic cancer
and male breast cancer [3]. Only 5-10% of all these can-
cers are actually related to one of several familial syn-
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and ovarian cancer syndrome due to mutations of these
tumor-suppressor genes [4]. Female carriers as compared
to the general population have therefore an increased life-
time risk to develop a breast and/or ovary cancer and are
also at life-time risk of developing other tumors. Cancer
predisposing mutations are considered to have a causative
role in 65% of families with hereditary breast and ovary
syndrome (HBOC syndrome) where are related to 60-
80% of breast tumor cases and 20-40% of ovarian tumors
[5]. In a 2003 report [6] the risk of breast and ovarian can-
cer for Ashkenazi women with inherited mutations in the
tumor suppressor genes BRCA1 and BRCA2 has been esti-
mated. On 1008 index cases, the lifetime risk of breast
cancer among female mutation carriers was 82%. Moreo-
ver, in the recent years, the risk increased: breast cancer
risk by age 50 among mutation carriers born before 1940
was 24%, but it was 67% among those born after 1940. In
the same study, the lifetime risk of ovarian cancer was
54% for BRCA1 and 23% for BRCA2 mutation carriers.
A recent meta-analysis estimated the mean cumulative
risk of developing breast and ovarian cancer by 70 years of
age [7]. The mean breast cancer risk for BRCA1 and
BRCA2 mutation carriers was 57% (95% CI, 47% - 66%)
and 49% (95% CI, 40% - 57%) respectively [7]. The ovar-
ian cancer risk for BRCA1 and BRCA2 mutation carriers
was 40% (95% CI, 35% - 46%) and 18% (95% CI, 13% -
23%) respectively [7]. On these findings, it can be esti-
mated that at least 15% of ovarian cancer cases are inher-
ited tumors linked to a mendellian autosomic dominant
inheritance of cancer predisposing mutations [8]. BRCA1/
2 mutations account for more than 90% of hereditary
ovarian cancer, whereas the remaining 10% is related to
MLH1 and MSH2 mutations [9]. The identification of
such genes in high risk female carriers provided valuable
insights for the understanding of the natural history and
pathogenesis of such diseases. It is an hard task to define
the true prevalence of BRCA1/2 cancer predisposing
mutations in the general population taking in account the
variable presentation in different ethnic groups. In a
recent study, it has been analyzed the prevalence of
BRCA1/2 related to ethnicity in non-Ashkenazy women
undergoing genetic testing from 1996 to 2006 [10]. Afro-
american and latin-american women were diagnosed as
carrier of BRCA1/2 mutations more commonly than
women of european ancestry (15.6% versus 12.1%) with a
clear increase of BRCA1 mutations as related to ethnicity
[10].
BRCA1 and BRCA2 gene function and role in the DNA 
repair
Tumor cells lacking BRCA1 or BRCA2 function are highly
genetically unstable. Important insights on BRCA1 func-
tional role in the DNA repair mechanism is shown by
physical interaction with RAD51 and BARD1 [11,12].
BRCA1 and BARD1 form a hetero-dimeric complex that
functions in a variety of cellular processes, including tran-
scriptional regulation, cell cycle progression and mainte-
nance of X chromosome inactivation. Several findings
suggest a specific role of BRCA1 and BARD1 in DNA
repair [13]. Cell lines defective for BRCA1 or BARD1
exhibit genomic instability, are sensitive to DNA damag-
ing agents and display defects in DNA double-strand
breaks (DSBs) repair by homologous recombination
(HR) [14]. Following exposure to DNA damaging agents,
BRCA1 and BARD1 form a nuclear complex at sites of
DNA damage where they colocalize with other DNA
repair proteins such as RAD51 [15]. BRCA1 is also phos-
phorylated during the cell cycle and following treatment
with genotoxic agents by the DNA damage checkpoint
kinases ATM and ATR [16].
Both BRCA1 and BARD1 possess RING and BRCT
domains. Recent studies suggest that the BRCT motifs may
function as a phosphopeptide-binding domain that may
be required for mediating protein-protein interactions
with phospho-proteins and the N-terminal RING
domains is responsible for tight association of the two
proteins. This motif also confers E3-ubiquitin ligase activ-
ity raising the possibility that BRCA1/BARD1 hetero-
dimer may specifically ubiquitinate proteins required for
transcription, cell cycle and/or DNA repair [17].
On these findings, BRCA1 and BRCA2 appear to be func-
tionally related to DNA repair mechanisms [18]. It is now
clear that BRCA1 plays a critical role in the DNA damage
recognition and in cell cycle checkpoints control that
allows cell cycle progression only after DNA repair, avoid-
ing genetic damage transmission in subsequent cell gener-
ations [19].
BRCA1 participates to a large multi-protein complex, the
BRCA1-associated genome surveillance complex (BASC)
[20], which acts as a sensor for DNA damage. BRCA2 has
however a more direct role in DNA repair itself by driving
RAD51 to the DSBs site [21]. Following recognition of
DNA DSBs, BRCA1 is phosphorylated and leads to activa-
tion of the DSB repair by HR [22]. HR is an error-free path-
way and operates the repair of DSBs in the late S and G2
phases of the cell cycle. An additional role of the HR is the
repair of DSBs which occur for stalling of replication fork
due to unrepaired single-strand breaks (SSB). In the
absence of functional BRCA1 or BRCA2, cells become
unable to undergo DNA repair by DSB and activate the
non-homologous end joining (NHEJ) and single-strand
non-homologous end-joining annealing (SSA), which are
error-prone DNA repair pathways. Deficiency in DSB
repair plays a crucial role in the chemo sensitivity profile
of BRCA1- and BRCA2-deficient cells. It has to be consid-Page 2 of 9
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gene expression by the BRCT domain.
Chemosensitivity of BRCA1/2-related ovarian tumors
1. Preclinical findings
It is now well known that tumor cells lacking BRCA1/2 are
highly sensitive to DNA damaging agents like platinum
derivatives, as a consequence of impaired genomic dam-
age repair which is induced by different mean [19,23].
Platinum compounds, through adduct formation at the
DNA produce DBS, are specifically active in tumors with
HR impairment for BRCA1/2 lack of function [24]. There
is strong evidence from preclinical and clinical studies for
a specific sensitivity of different BRCA1/2-related tumors
to platinum derivatives. In 2003 our group has demon-
strated a differential chemosensitivity profile in vitro of
BRCA1-mutated HCC1937 breast cancer cells with bi-
allelic loss as compared to the derivative clone
HCC1937WT, where the BRCA1 expression has been
reconstituted by transfection of a BRCA1 full length cDNA
[25]. This study led to the conclusion that HCC1937 are
highly sensitive to Cisplatinum (CDDP) as compared to
Estrogen Receptor expressing and BRCA1-competent
MCF-7 and BRCA1-reconstituted HCC1937WT. In the
same work it was demonstrated that BRCA1-defective
HCC1937 breast cancer cells were resistant to paclitaxel as
compared to MCF-7 and HCC1937WT cells. In a further
study by our group a differential chemosensitivity of
BRCA1-mutated HCC1937 human breast cancer cells to
microtubule-interfering agents has been found [26]
Quinn et al. in a similar cell system, where BRCA1 was
reconstituted by a retroviral vector containing the full
length cDNA and compared to parental cells infected with
empty vector, demonstrated that BRCA1 functions as a
differential modulator of chemotherapy-induced apopto-
sis. [27]. In a recent follow up study [28], our group eval-
uated the in vivo differential chemosensitivity of BRCA1-
defective versus BRCA1-reconstrituted xenografts in SCID
mice. In this mouse model, we confirmed a differential
and higher activity of CDDP against HCC1937 BRCA1-
defective xenografts. Furthermore, we demonstrated a
major difference in the whole gene expression profile by
cDNA microarray. Specifically, we found reduced expres-
sion of ERCC1 and RRM1 in HCC1937 versus BRCA1-
reconstitued parental cells. Importantly, these two genes
have been demonstrated to correlate, in previous studies
in lung cancer, to an impaired response to CDDP treat-
ment and to improved survival in patients undergoing
treatment with CDDP/gemcitabine [29,30]. In addition,
we found increased expression of mRNAs for RAD52 and
XRCC1, genes related to DNA damage recognition. These
latter findings strongly suggest a compensatory response
to the impaired DNA damage repair in BRCA1 defective
cells.
All together these experimental observations suggest that
sensitivity to platinum derivatives inversely correlates to
sensitivity to paclitaxel in BRCA1-defective breast tumor
cells. Quinn et al. [31] have recently demonstrated a direct
correlation between BRCA1 mRNA expression levels and
overall survival in patients with ovarian cancer undergo-
ing chemotherapy. These authors have shown that inhibi-
tion of BRCA1 expression in ovarian cancer cell lines
increases cell sensitivity to platinum derivatives, while
reduces the antitumor activity of taxanes. Subsequently
they have evaluated BRCA1 mRNA expression in 70 tissue
samples in sporadic ovarian tumors from patients which
underwent treatment with platinum derivatives and they
found that patients with low-intermediate levels of
BRCA1 mRNA had a significantly better outcome in terms
of overall survival (OS) as compared to high BRCA1
mRNA levels (57.2 months versus 18.2 months p =
0.0017). Finally high BRCA1 mRNA tumor carriers had a
better survival if treated with taxanes even if statistical sig-
nificance was not reached. It was concluded that BRCA1
mRNA expression levels correlate in sporadic ovarian can-
cer patients with OS and can be considered a predictive
marker of treatment response. More recently the same
authors have produced a systematic review [32] on all
published studies on this topic from 1990 to 2008 leading
to the hypothesis of a possible role of BRCA1 as biomar-
ker predictive of treatment response in hereditary and
sporadic ovarian tumors. The authors conclude that the
identification of a functional deficit in BRCA1 and in
related pathways is likely to provide information on treat-
ment efficacy. Finally, the same authors have provided
evidence that BRCA1 protein expression may be a predic-
tive marker of chemotherapy response in sporadic epithe-
lial ovarian cancer. They found that BRCA1 protein
expression is associated with a better outcome of plati-
num/taxane combination as compared with CDDP alone,
while when BRCA1 protein was not detected CDDP alone
was as effective as combination chemotherapy. These data
indicate again that CDDP alone may be highly effective in
the case of BRCA1 impairment [33].
It is a common finding that human tumors highly sensi-
tive to chemotherapy may become resistant [34]. Recent
studies have shown that even the increased sensitivity to
CDDP or Poly ADP Ribose Polymerase (PARP) inhibitors
(see below) produced by BRCA1/2 gene mutation is not a
stable trait [35]. Stacey Edwards et al have demonstrated
that when pancreatic cells with BRCA2 inactivation
become resistant to PARP inhibitors, novel BRCA2 iso-
forms were detected in the resistant line resulting from
intragenic deletion of the c.6174delT mutation and resto-
ration of the open reading-frame (ORF) [36]. Similarly
Wataru Sakai et al. reported that secondary mutations in
BRCA2 might reconstitute resistance to CDDP and PARP
inhibitors in BRCA2 mutated tumors and that similarPage 3 of 9
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resistance to CDDP by ovarian tumors as demonstrated
on clinical specimens [37].
All together these findings indicate that BRCA1/2 gene-
mediated sensitivity to anticancer treatment can be
reverted by escape mutations and that these important
events must be taken in account for the design of novel
therapeutic strategies in this specific setting.
2. Clinical findings
Preliminary clinical evidence appears in line with preclin-
ical in vitro findings and indicates that prospective clinical
trials must be designed to clarify the clinical relevance of
the differential sensitivity to anticancer drugs by BRCA1/2
mutated tumors.
In the last few years, the identification of individuals car-
riers of inactivating mutations on BRCA1 and 2 genes has
been essentially directed to cancer prevention by the use
of prophylactic surgery [38,39], preventive treatments or
screening procedures different from general population
[40-43]. Even with such measures, the onset of ovarian
cancer in mutation carriers is a common event for failure
of preventive strategies or because cancer predisposing
mutations have been identified when the cancer has been
already diagnosed. It is therefore often necessary the use
of systemic chemotherapy regimens, which at present do
not differ from those which are utilized in sporadic
tumors. At present, ovary tumors are still a fatal disease in
a high percentage of patients, due to late diagnosis for the
lack of symptoms in early stage disease and partially for
the intrinsic biologic aggressiveness. Systemic treatments
are needed not only in advanced/metastatic disease but
also in early cases and are based on the use of agents like
platinum derivatives, taxanes, topotecan and liposomal
doxorubicin.
The hereditary variants are characterized by typical clinical
features, which often allow the selection of patients for
genetic counseling and testing procedures, as early onset,
multiple tumors especially in the breast, and family his-
tory for the same or other BRCA1/2 related tumors.
The increased risk of developing a ovary tumor in BRCA1/
2 mutation carriers, assessed as 15,3% of the whole ovary
cancer patients [44], has been related to the different func-
tions of BRCA1 and 2 genes in the regulation of cell
growth, genomic stability and repair of genomic damage
by homologous recombination. Specifically, this last fea-
ture is the cause of the DSBs repair failure resulting in
genomic instability and predisposition to neoplastic
transformation for loss of function of BRCA1/2.
As regard to the clinical outcome of BRCA1/2-related
breast tumors, several studies have been done in order to
evaluate if germ-line cancer predisposing mutations
might be useful for inclusion in different prognostic sub-
groups [43]. The majority of published studies has not
produced proof of prognostic value of BRCA1/2 inherit-
ance. Such studies present however several majors flaws
for the retrospective design and because patients where
not considered on the basis of stage, age, histology and
residual disease after primary surgery[38].
A recent case-control study [45] included 779 jewish
women affected by hereditary ovarian cancer who had
undergone genetic testing for three Askhenazi founder
mutations (BRCA1 185delAG, 5382insC; BRCA2
617delT). The design of the study was based on the com-
parison of mutation-positive versus mutation-negative
ovarian cancer carriers in terms of long term outcome. The
two groups were homogeneous for known prognostic,
clinical and demographic factors.
This study clearly demonstrated a significantly better 5
years survival in mutation carriers as compared to non-
carrier individuals (34.4% surviving in the non carriers
versus 46% in the BRCA mutation carriers p = 0.003). The
survival gain occurred in advanced stages but not in early
stages and at multivariate analysis, the prognostic weight
of BRCA1/2 mutation was independent from age at diag-
nosis, histology and grading. Subgroup analysis demon-
strated a better outcome for BRCA2-related versus BRCA1-
related or BRCA-unrelated, while BRCA1-related did not
behave favorably if compared to the two other subgroups.
Interpretation of these subgroup analysis needs caution
however at this point and confirmation in larger studies is
eagerly awaited.
Data from this study appear of interest but it has to be
considered that it is difficult to generalize these findings to
non-Askhenazi population with a more heterogeneous
mutational status, to evaluate the impact of BRCA1 versus
BRCA2 as well as to speculate on the potential role of
other confounding factors or modifier genes which might
by themselves retain a prognostic weight. Moreover this
study doesn't allow to understand if the survival advan-
tage achieved in BRCA1/2 mutation carriers as compared
to non carriers might be related to intrinsic biologic fea-
tures or to a better response to treatment. In any case this
landmark study provides proof of principle that ovarian
cancer arising in BRCA1/2 mutation carriers is a different
disease.
Norah Kauff [38,46] has discussed these important find-
ings in a provocative Journal of Clinical Oncology editorial.
The identification of BRCA1/2 related ovarian cancer as a
distinct disease has important implications. Imbalance ofPage 4 of 9
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omized trial will introduce a powerful bias. It can be
therefore inferred that all ovarian cancer patients enrolled
in prospective randomized trials might be stratified on the
basis of presence or absence of BRCA1/2 cancer predispos-
ing mutations. These points merit further discussion.
BRCA1/2 testing is an expensive procedure and has
important ethical/consent implications. We think that
prospective genetic testing cannot be performed in unse-
lected individuals. We think however that enrollment in
ovarian cancer clinical trials should be reserved to clinical
centers offering genetic counseling to all ovarian cancer
patients. Genetic testing based on pretesting counseling
will allow the identification of most BRCA1/2 related
tumors. In any way, Kauff's point needs to be considered
in the planning of future clinical research in ovarian can-
cer.
BRCA-ness in the current scenario of management of 
ovarian cancer
Important information has been derived from a mono-
institutional case-control study recently reported by Tan et
al. [46]. The authors confirm a more favorable outcome in
BRCA1/2 mutation carriers with a significant advantage in
OS and demonstrate a differential chemosensitivity. A
clear advantage in the treatment free interval (TFI) is
achieved in BRCA1/2 related tumors when patients are
treated with platinum-containing regimens in different
lines of treatment (median 15 months for BRCA1/2 versus
9 months for non BRCA1/2, first to second line p = 0.001;
median 15 months for BRCA1/2 versus 5.6 months for
non BRCA1/2 p = 0.002 second to third line). The better
TFI is paralleled by an higher level of radiological
responses (Overall Response Rate, ORR 95.5% for
BRCA1/2 mutated versus 59.1% for non BRCA1/2 p =
0.002 in first line treatment). On the other hand, BRCA1/
2 tumors did not show an increased benefit from non
platinum-based chemotherapy regimens (median TFI 4
months for BRCA1/2 versus 6 for non BRCA1/2 second to
third line p = 0.831). This study indicates that BRCA1/2
related ovarian cancers have a better outcome because are
intrinsically highly sensitive to platinum containing
chemotherapy. The authors provide evidence for a
"BRCA-ness" syndrome in BRCA1/2 mutation carriers
which includes serous histology, high response to first
and subsequent lines of platinum-based treatment, longer
TFIs between relapses, and improved OS.
BRCA-ness in the evolving scenario
The pharmacologic interference with alternative genomic
damage repair pathways as those related to single strand
break repair (SSBRs) might be of relevance for hereditary
BRCA1/2 related tumors [47-49]. It is a recent finding the
identification of an enzyme family the PARPs, which
includes different molecules with different activity and
function, some of them strictly related to the Base Exci-
sion Repair (BER), which is involved in the SSBRs. PARP1
is the most studied enzyme in this family and is involved
through BER activation in the cellular response to
genomic damage produced by geno-toxic stress. PARP1
binds to the sites of damage at the single strand and cata-
lyzes the synthesis and subsequent transfer of chains of
poly-(ADP)-ribose (PAR) to carboxylic groups of several
proteins, including PARP1 itself. This enzyme uses nicoti-
namide adenine dinucleotide (NAD+) as substrate to syn-
thesize poly(ADP)-ribose and leads to a series of linear or
branched polymers of PAR [21]. PARP1 contains three
functionally distinct domains: an amino-terminal DNA-
binding domain (DBD), an auto-modification domain
(AD), which is linked to BRCT-domain of BRCA1, and a
carboxyl-terminal PARP homology domain, that includes
the catalytic domain (CAT) responsible for PAR formation
[50]. The ADP-ribosilation creates target sites of SSBs neg-
atively charged that recruit the enzymes needed to form
BER multiprotein complex, such as: XRCC1(X-ray repair
cross-complementing 1), DNA ligase III and DNA-
polymerase. Following poly-(ADP)-ribosylation, PARP1
loses affinity for DNA, detaches and exposes sites of dam-
age, thereby allowing access to DNA to repair enzymes;
PARP1 subsequently undergoes degradation. It has been
hypothesized that, in addition to SSB-repair PARP1 plays
also a critical role in double-strand breaks(DSBs)-repair,
although at present no direct functional correlation has
been demonstrated with the nonhomologous end joining
(NHEJ) or HR. PARPs system is involved not only in
repair mechanisms, but also in transcriptional regulation,
plays a key role in regulation of cell death and survival and
represents an important regulatory factor in the molecular
events leading to the development of cancer or inflamma-
tory disease. In vitro and in vivo studies support the use of
PARP inhibitors not only as chemo and radiosensitizing
agents, but also as selective agents in those tumors carry-
ing specific functional defects in DNA repair mechanisms,
such as cancers harboring specific mutations of BRCA1
and 2. Indeed, when SSB repair is inactivated by PARP1
pharmacological inhibition during S-phase, DNA DSBs
are induced. This latter effect may confer synthetic
lethality to cells with defective homology-directed DSB
repair like cells with BRCA1 and BRCA2 deficiency (Figure
1) [21,51,52].
The finding that BRCA1/2 deficient cells are highly sensi-
tive to PARP inhibition [53] has opened a new avenue of
research for treatment and prevention of tumors arising in
the context of BRCA1/2 mutation or which might have
somatic impairment of such pathways, such as basal-like
breast cancer. Rottemberg et al. have recently demon-
strated in a genetically engineered mouse model of
BRCA1 related-breast tumor that the PARP inhibitor
AZD2281 (olaparib) is highly effective alone or in combi-Page 5 of 9
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ently available and under investigation in clinical trials
(Table 1). A seminal phase I trial has provided evidence
that olaparib is well tolerated, inhibits PARP activity in
surrogate samples and also in tumor samples and exerts
activity against BRCA1/2 related cancer [55]. Very recently
a phase II trial with olaparib has been reported in BRCA1/
2 deficient ovarian cancer. Olaparib has been given orally
in 28 days cycles initially at the MTD 400 mg bis in die
(bd) (33 patients) and subsequently at 100 mg bd (24
patients) The confirmed RECIST ORR was 33% at 400 mg
bd and 12.5% at 100 mg bd. These data clearly show that
Olaparib is highly effective in advanced pretreated
BRCA1/2 related ovarian cancer [56]. Olaparib appears
therefore an attractive option for use in earlier phases of
disease and to be evaluated in combination with plati-
num derivatives on the bases of important preclinical
studies. Results from ongoing trials are eagerly awaited.
Conclusion
All together these findings introduce a provocative novel
scenario where BRCA1/2 carcinogenetic process in the
hereditary setting produces novel opportunities for phar-
macological intervention. Apart novel drugs like PARP
inhibitors, these findings may allow a different and more
rational approach for the treatment of BRCA1/2 related
ovarian tumors by currently available drugs. The study by
Tan et al[46] clearly demonstrates that CDDP resistance in
BRCA1/2-related tumors is a late event and patients expe-
rience a long treatment free interval after CDDP-based
DNA repair defects and therapeutic intervention in BRCA1/2 defective tumorsFigure 1
DNA repair defects and therapeutic intervention in BRCA1/2 defective tumors. Following DNA damage poly(ADP-
ribose) polymerases (PARP), specifically PARP-1 and PARP-2, are activated and bind to the exposed Single Strand Breaks 
(SSBs). Pharmacological inhibition of PARP1 with PARP-inhibitors leads to a block in the repair of SSBs, resulting in the block-
age of replication fork and subsequent conversion of damage in DSBs. In hereditary cancers harboring BRCA1/BRCA2 muta-
tions, this system is inefficient and therefore the tumor cells lacking this survival mechanism undergo cell death. The antitumor 
activity of PARP inhibitors may be enhanced by combination with chemotherapeutic agents which induce direct damage to 
DNA, such as platinum derivatives.
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effective in preclinical models of BRCA1/2 models would
suggest a more rational first line treatment with CDDP/
gemcitabine combination or even with carboplatin esca-
lated doses in order to achieve the maximal benefit in
advance of the occurrence of escape mutations like those
recently described in BRCA2 gene. All these approaches
need of course to be explored in well designed prospective
clinical trials. The finding by Quinn et al[31] and by
Carser et al. [33] that low BRCA1 mRNA and protein
expression is predictive of specific benefit of platinum
based chemotherapy, while high BRCA1 mRNA might
predict for benefit of taxane treatment, might allow to
explore the potential advantage of molecular marker-
based treatment assignment compared to conventional
assignment. This topic is prospectively evaluated in non
small cell lung cancer (NSCLC) by Rosell and cowork-
ers[29,30,57].
Treatment tailoring of ovarian cancer on the genetic back-
ground appears now to be based on a robust rationale
from preclinical and clinical evidence and it is time to
undergo evaluation in well designed prospective trials.
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